Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Octanoylcarnitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 2/20 | 0.74 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.72 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.97 |
| ▸ | MEN1 | O00255 | 5/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.97 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.97 |
| ▸ | TP53 | P04637 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.97 |
| ▸ | THPO | P40225 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octanoylcarnitine SCHEMBL2787592 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Hydrochloric Acid SCHEMBL5499645 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Hydrochloric Acid SCHEMBL307401 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL527281 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL1332594 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Hydrochloric Acid SCHEMBL5499648 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Octanoylcarnitine SCHEMBL2784153 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Hydrochloric Acid SCHEMBL6676390 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Hydrochloric Acid SCHEMBL5499600 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Hydrochloric Acid SCHEMBL17395722 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054124-A1 | HAIR TREATMENT PRODUCTS COMPRISING POLYMERS | Henkel AG & Co. KGaA (DE) | 2009-05-06 | — | — | EP | claimed |
| EP-2054015-A1 | AGENTS CONTAINING BIOQUINONES AND BETAINES | Henkel AG & Co. KGaA (DE) | 2009-05-06 | — | — | EP | claimed |
| WO-2008049701-A1 | HAIR TREATMENT PRODUCTS COMPRISING POLYMERS | HENKEL AG & CO. KGAA (DE) | 2008-05-02 | — | — | WO | claimed |
| WO-2008028775-A1 | AGENTS CONTAINING BIOQUINONES AND BETAINES | HENKEL AG & CO. KGAA (DE) | 2008-03-13 | — | — | WO | claimed |
| EP-2352484-A1 | HAIR CONDITIONERS COMPRISING IMIDAZOLINES AND ESTER OILS | Henkel AG & Co. KGaA (DE) | 2011-08-10 | — | — | EP | disclosed |
| US-20110033407-A1 | Hair Treatment Means With Cloudberry Extract | HENKEL AG & CO. KGAA (DE) | 2011-02-10 | — | — | US | disclosed |
| EP-2262473-A2 | HAIR TREATMENT MEANS WITH CLOUDBERRY EXTRACT | Henkel AG & Co. KGaA (DE) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010063565-A1 | HAIR CONDITIONERS COMPRISING IMIDAZOLINES AND ESTER OILS | HENKEL AG & CO. KGAA (DE) | 2010-06-10 | — | — | WO | disclosed |
| WO-2009127564-A2 | HAIR TREATMENT MEANS WITH CLOUDBERRY EXTRACT | HENKEL AG & CO. KGAA (DE) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009074464-A2 | HAIR-CONDITIONING PRODUCTS CONTAINING CATIONIC COMPOUNDS AND SELECTED SILICONES AND/OR COSMETIC OILS | HENKEL AG & CO. KGAA (DE) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009074463-A2 | HAIR-CONDITIONING PRODUCTS CONTAINING IMIDAZOLINES AND SELECTED SILICONES AND/OR COSMETIC OILS | HENKEL AG & CO. KGAA (DE) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009074465-A2 | HAIR-CONDITIONING PRODUCTS CONTAINING CATIONIC BEHENYL COMPOUNDS AND SELECTED SILICONES AND/OR COSMETIC OILS | HENKEL AG & CO. KGAA (DE) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033407-A1 | Hair Treatment Means With Cloudberry Extract | KRT18, TUBB8, TUBB6 | HSP90AA1 388/4885GLA 407/4885HRH1 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.